PubRank

Hans-Peter Hartung

Author PubWeight™ 338.70‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 24.22
2 Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010 13.82
3 Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 13.23
4 Guillain-Barré syndrome. N Engl J Med 2012 6.28
5 Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012 4.25
6 Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012 3.89
7 Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008 3.59
8 Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011 3.52
9 Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009 3.42
10 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009 3.37
11 Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 3.29
12 MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014 3.27
13 Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010 3.26
14 Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 2003 3.22
15 Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011 3.16
16 Acute disseminated encephalomyelitis: an update. Arch Neurol 2005 2.45
17 Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010 2.32
18 New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002 2.21
19 Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011 2.19
20 Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012 2.12
21 Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007 2.06
22 Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005 2.06
23 The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008 2.01
24 Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005 1.92
25 Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol 2012 1.84
26 Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005 1.79
27 Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006 1.79
28 Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 2012 1.77
29 Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013 1.76
30 More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med 2016 1.73
31 Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004 1.69
32 Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry 2012 1.66
33 Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 2003 1.65
34 Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain 2007 1.63
35 Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler 2011 1.57
36 Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology 2013 1.56
37 Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006 1.54
38 Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol 2003 1.48
39 Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 2012 1.47
40 Towards individualised multiple-sclerosis therapy. Lancet Neurol 2005 1.46
41 Neuromyelitis optica following human papillomavirus vaccination. Neurology 2012 1.44
42 Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol 2009 1.42
43 Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol 2005 1.40
44 Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother 2012 1.40
45 Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003 1.39
46 Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010 1.37
47 Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007 1.36
48 Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010 1.36
49 Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol 2007 1.34
50 Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler 2013 1.30
51 Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2009 1.28
52 Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013 1.27
53 Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol 2005 1.25
54 Enhancing remyelination in disease--can we wrap it up? Brain 2011 1.25
55 Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008 1.25
56 Optical coherence tomography in parkinsonian syndromes. PLoS One 2012 1.24
57 In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004 1.24
58 Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012 1.24
59 Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors. Ann Neurol 2009 1.24
60 Animal models of multiple sclerosis--potentials and limitations. Prog Neurobiol 2010 1.23
61 Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review. Arch Neurol 2003 1.22
62 Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009 1.22
63 The complex world of oligodendroglial differentiation inhibitors. Ann Neurol 2011 1.19
64 Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006 1.17
65 New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009 1.15
66 From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007 1.14
67 Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005 1.13
68 Remyelinating strategies for the treatment of multiple sclerosis. Prog Neurobiol 2002 1.12
69 Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2009 1.12
70 Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010 1.11
71 Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005 1.10
72 Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007 1.09
73 Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain 2006 1.09
74 Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012 1.09
75 Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004 1.09
76 Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002 1.08
77 Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol 2007 1.08
78 Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010 1.07
79 Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve 2013 1.06
80 Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol 2011 1.06
81 Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2012 1.04
82 Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol 2013 1.04
83 Immune circuitry in the peripheral nervous system. Curr Opin Neurol 2006 1.03
84 Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. Stroke 2007 1.03
85 Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol 2011 1.02
86 Development and pharmacological modulation of embryonic stem cell-derived neuronal network activity. Exp Neurol 2007 1.02
87 Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003 1.01
88 Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 2007 1.01
89 Statins--a cure-all for the brain? Nat Rev Neurosci 2005 1.00
90 Activation of CXCR7 receptor promotes oligodendroglial cell maturation. Ann Neurol 2010 0.99
91 Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014 0.99
92 CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 2010 0.98
93 HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008 0.98
94 Niche-dependent development of functional neuronal networks from embryonic stem cell-derived neural populations. BMC Neurosci 2009 0.98
95 Osteopontin, a macrophage-derived matricellular glycoprotein, inhibits axon outgrowth. FASEB J 2004 0.97
96 Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models. J Immunol Methods 2010 0.96
97 Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 2007 0.96
98 Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis. J Neurol 2007 0.96
99 Neurofilament ELISA validation. J Immunol Methods 2009 0.96
100 Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol 2007 0.96
101 European validation of a standardized clinical description of multiple sclerosis. J Neurol 2004 0.96
102 Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet 2013 0.96
103 Managing the risks of immunosuppression. Curr Opin Neurol 2011 0.96
104 MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain 2013 0.94
105 Patterns of retinal damage facilitate differential diagnosis between Susac syndrome and MS. PLoS One 2012 0.94
106 Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007 0.94
107 CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 2003 0.94
108 The immunocompetence of Schwann cells. Muscle Nerve 2008 0.93
109 GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther 2012 0.93
110 Matrix metalloproteinase-2 is involved in myelination of dorsal root ganglia neurons. Glia 2009 0.93
111 Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010 0.93
112 Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. Curr Opin Neurol 2002 0.92
113 Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol 2011 0.92
114 Significant clinical, neuropathological and behavioural recovery from acute spinal cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood. Brain 2011 0.92
115 Are statins a treatment option for multiple sclerosis? Lancet Neurol 2004 0.92
116 Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010 0.92
117 Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol 2005 0.92
118 ADAM-10 and ADAM-17 in the inflamed human CNS. Glia 2003 0.92
119 Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 2012 0.91
120 Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 2012 0.91
121 Restoring neuronal function after stroke by cell replacement: anatomic and functional considerations. Stroke 2011 0.91
122 The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol 2008 0.91
123 Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 2007 0.91
124 CD8+ phagocyte recruitment in rat experimental autoimmune encephalomyelitis: association with inflammatory tissue destruction. Am J Pathol 2003 0.91
125 Inflammatory demyelinating brain lesions heralding primary CNS lymphoma. Can J Neurol Sci 2012 0.90
126 A new role for interferon gamma in neural stem/precursor cell dysregulation. Mol Neurodegener 2011 0.90
127 Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity. J Neurol 2008 0.90
128 Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 2006 0.90
129 Retinal neurodegeneration in Wilson's disease revealed by spectral domain optical coherence tomography. PLoS One 2012 0.89
130 An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Mult Scler 2013 0.89
131 Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002 0.89
132 Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2004 0.89
133 Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 2010 0.89
134 Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 2006 0.89
135 Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2006 0.89
136 Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord 2009 0.88
137 Treatment of active secondary progressive multiple sclerosis with treosulfan. J Neurol 2007 0.88
138 Exclusion of serine palmitoyltransferase long chain base subunit 2 (SPTLC2) as a common cause for hereditary sensory neuropathy. Neuromuscul Disord 2002 0.88
139 High throughput analysis of TCR-beta rearrangement and gene expression in single T cells. Lab Invest 2006 0.88
140 Biologic role of interferon beta in multiple sclerosis. J Neurol 2004 0.87
141 Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol 2009 0.86
142 Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 2007 0.86
143 Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother 2007 0.86
144 Variants of Guillain-Barré syndrome: low incidence but high impact. J Neurol 2009 0.86
145 Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. J Med Genet 2012 0.86
146 'Bubbles in the brain': retrograde venous air embolism in the cavernous sinus. Eur Neurol 2009 0.85
147 Histone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiation. Glia 2012 0.85
148 Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice. Stroke 2012 0.85
149 Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol 2010 0.85
150 Mechanisms of mitoxantrone in multiple sclerosis--what is known? J Neurol Sci 2004 0.85
151 p57kip2 regulates glial fate decision in adult neural stem cells. Development 2012 0.85
152 Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 2010 0.85
153 Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia 2010 0.85
154 Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Mult Scler 2013 0.84
155 Hashimoto encephalopathy following iodine 131 (131 I) radiotherapy of Graves disease. Arch Neurol 2008 0.84
156 Multiple sclerosis--novel insights and new therapeutic strategies. Curr Opin Neurol 2005 0.84
157 Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 2008 0.84
158 Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci 2013 0.84
159 p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. Proc Natl Acad Sci U S A 2009 0.84
160 CD8 T-cell subsets and viral load in the cerebrospinal fluid of therapy-naive HIV-infected individuals. AIDS 2007 0.84
161 Pharmacological treatment of early multiple sclerosis. Drugs 2008 0.84
162 The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis 2007 0.84
163 Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009 0.84
164 Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. J Neurol 2011 0.83
165 Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol 2008 0.83
166 Chronic inflammatory demyelinating polyneuropathy--update on pathogenesis, diagnostic criteria and therapy. Curr Opin Neurol 2005 0.83
167 Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. Pharmacoepidemiol Drug Saf 2014 0.83
168 Role of nitric oxide as mediator of nerve injury in inflammatory neuropathies. J Neuropathol Exp Neurol 2007 0.83
169 Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation. Neurobiol Dis 2009 0.83
170 Prion proteins: physiological functions and role in neurological disorders. J Neurol Sci 2007 0.83
171 Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS One 2011 0.83
172 Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies. Brain 2008 0.83
173 Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler 2013 0.82
174 Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies. Exp Neurol 2006 0.82
175 Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate. J Neurol Sci 2005 0.82
176 The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation 2013 0.82
177 Risks and benefits of multiple sclerosis therapies: need for continual assessment? Curr Opin Neurol 2011 0.82
178 Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006 0.82
179 Plasma exchange in immune-mediated neuropathies. Curr Opin Neurol 2008 0.82
180 Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 2005 0.82
181 Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array. J Neurovirol 2009 0.82
182 Neural precursor cells as a novel target for interferon-beta. Neuropharmacology 2008 0.81
183 Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann Neurol 2009 0.81
184 Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 2004 0.81
185 Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS. Exp Neurol 2007 0.81
186 Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005 0.81
187 Mesenchymal stem cell conditioning promotes rat oligodendroglial cell maturation. PLoS One 2013 0.81
188 Ammonium chloride influences in vitro-neuronal network activity. Exp Neurol 2012 0.81
189 Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011 0.81
190 Therapeutic strategies in the Guillain-Barré syndrome. Semin Neurol 2003 0.81
191 Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol 2014 0.81
192 Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle Nerve 2014 0.81
193 Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010 0.80
194 Tissue mRNA expression in rat of newly described matrix metalloproteinases. Biol Res 2005 0.80
195 Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007 0.80
196 Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 2009 0.80
197 New immunopathologic insights into multiple sclerosis. Curr Neurol Neurosci Rep 2003 0.80
198 Novel therapeutic options for multiple sclerosis. Expert Rev Clin Pharmacol 2013 0.80
199 The future of multiple sclerosis therapy. Pharmacol Res 2009 0.80
200 In vitro neuronal network activity in NMDA receptor encephalitis. BMC Neurosci 2013 0.80
201 Autoimmunity and inflammation in the peripheral nervous system. Trends Neurosci 2002 0.80
202 Cytokine levels in CSF and neuropsychological performance in HIV patients. J Neurovirol 2012 0.80
203 Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther Adv Neurol Disord 2012 0.80
204 Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol 2010 0.79
205 Treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Handb Clin Neurol 2013 0.79
206 Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2010 0.79
207 Bimanual recoupling by visual cueing in callosal disconnection. Neurocase 2004 0.79
208 p57 kip2's role beyond Schwann cell cycle control. Cell Cycle 2008 0.79
209 Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2011 0.79
210 Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve. Neurology 2003 0.79
211 Interferon beta in multiple sclerosis: predicting response at an early stage. J Neurol Neurosurg Psychiatry 2008 0.79
212 Neuroimmunology: Assessing the value of plasma exchange in neurology. Nat Rev Neurol 2011 0.79
213 Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis. Clin Ther 2012 0.79
214 Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Arch Neurol 2010 0.79
215 Age-dependent modulation of cortical transcriptomes in spinal cord injury and repair. PLoS One 2012 0.79
216 Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics 2014 0.79
217 Word deafness as a cortical auditory processing deficit: a case report with MEG. Neurocase 2008 0.78
218 Interferon gamma and sonic hedgehog signaling are required to dysregulate murine neural stem/precursor cells. PLoS One 2012 0.78
219 Intracranial venous pressure is normal in patients with multiple sclerosis. Mult Scler 2011 0.78
220 Recent developments and future directions in Guillain-Barré syndrome. J Peripher Nerv Syst 2012 0.78
221 The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 2008 0.78
222 Severe relapse of multiple sclerosis during plasma exchange treatment. Mult Scler 2011 0.78
223 Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al. J Neurol 2011 0.78
224 Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles. CNS Drugs 2005 0.78
225 Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease. Eur J Nucl Med Mol Imaging 2014 0.78
226 Guillain-Barré syndrome variant with prominent facial diplegia, limb paresthesia, and brisk reflexes. J Neurol 2011 0.77
227 Autoimmunity in the peripheral nervous system. Crit Rev Neurobiol 2003 0.77
228 Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2011 0.77
229 Repair strategies for multiple sclerosis: challenges, achievements and perspectives. Curr Opin Neurol 2016 0.77
230 Differential patterns of local gene regulation in crush lesions of the rat optic and sciatic nerve: relevance to posttraumatic regeneration. Cell Physiol Biochem 2010 0.77
231 Is 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunity. Exp Neurol 2009 0.77
232 Oligodendroglial lineage cells express nuclear p57kip2 in multiple sclerosis lesions. Glia 2013 0.77
233 Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system. J Peripher Nerv Syst 2005 0.77
234 Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies? Arch Neurol 2012 0.77
235 Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. Neurogenetics 2011 0.77
236 Cladribine as a therapeutic option in multiple sclerosis. Clin Immunol 2011 0.77
237 Is It Too Early to Predict the Failure of Natalizumab in NMO?-Reply. Arch Neurol 2012 0.76
238 Type III systemic allergic reaction to natalizumab. Arch Neurol 2008 0.76
239 Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol 2014 0.76
240 Interleukin-17 impedes Schwann cell-mediated myelination. J Neuroinflammation 2014 0.76
241 10 years of interferon beta-1b (Beta feron therapy. J Neurol 2005 0.76
242 Persistent organic personality change as rare psychiatric manifestation of MELAS syndrome. J Neurol 2003 0.76
243 CD19 as a molecular target in CNS autoimmunity. Acta Neuropathol 2014 0.76
244 Interferons in relapsing remitting multiple sclerosis. Lancet 2003 0.76
245 Beyond axonal transection: hippocampal damage in multiple sclerosis. Ann Neurol 2011 0.76
246 Oral therapies for multiple sclerosis: are we there yet? Lancet Neurol 2010 0.76
247 Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. Arch Neurol 2006 0.76
248 Peripheral neuropathies: Establishing common clinical research standards for CIDP. Nat Rev Neurol 2011 0.76
249 Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization. J Neurosci Res 2004 0.76
250 Mitoxantrone in multiple sclerosis. Adv Neurol 2006 0.75
251 Varicella-zoster virus: another trigger of Guillain-Barré syndrome? Clin Infect Dis 2010 0.75
252 Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. J Neurol 2009 0.75
253 Progress in untying the Gordian nodes of Ranvier in Guillain-Barré Syndrome. Exp Neurol 2012 0.75
254 The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 2006 0.75
255 Recent achievements in stem cell-mediated myelin repair. Curr Opin Neurol 2016 0.75
256 Promoting myelination in an in vitro mouse model of the peripheral nervous system: the effect of wine ingredients [corrected]. PLoS One 2013 0.75
257 Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis. Neurology 2006 0.75
258 Targeting two-pore domain potassium channels - a promising strategy for treating T cell mediated autoimmunity. Exp Neurol 2013 0.75
259 Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord 2012 0.75
260 Multiple paradigm shifts in multiple sclerosis. Curr Opin Neurol 2003 0.75
261 Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules. PLoS One 2011 0.75
262 Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards. J Neural Transm (Vienna) 2013 0.75
263 Fine-tuning the homeostasis of regulatory T cells: new mechanism of immunomodulatory therapy in multiple sclerosis. Arch Neurol 2008 0.75
264 An emboligenic pulmonary abscess leading to ischemic stroke and secondary brain abscess. BMC Neurol 2012 0.75
265 Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug Des Devel Ther 2010 0.75
266 The prefaces of Charcot: leitmotifs of an international career. Neurology 2003 0.75
267 Re: Errors in the editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670-1672]. Mult Scler 2013 0.75
268 Temporary leukocyte effects in temporal lobe epilepsy? Exp Neurol 2008 0.75
269 Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Curr Opin Neurol 2016 0.75
270 Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection"). Neurotherapeutics 2015 0.75
271 Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Dtsch Arztebl Int 2016 0.75
272 The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. J Neuroimmunol 2003 0.75
273 Untired regulatory T cells: untying fatigue from T cell regulation in multiple sclerosis. Eur Neurol 2009 0.75
274 Autoantibody-mediated dysfunction of sympathetic neurons in guillain-barre syndrome. Arch Neurol 2010 0.75
275 Immune-mediated neuropathies. Adv Neurol 2002 0.75
276 New diagnostic options in tuberculous meningitis? Int J Tuberc Lung Dis 2006 0.75
277 Brachial amyotrophic diparesis associated with anti-Hu positive anterior horn cell disease and autonomic disorder. J Neurol 2012 0.75
278 Advances in biotechnology and novel insights into pathophysiology have contributed to an increased understanding of the pathomechanisms of diseases affecting the peripheral nervous system. Curr Opin Neurol 2008 0.75
279 Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Rev Clin Pharmacol 2012 0.75
280 Biomarkers in the diagnosis and therapy of CIDP: Proceedings of the Biomarkers Faculty Meeting; June 8-9, 2010, Athens, Greece. J Peripher Nerv Syst 2011 0.75
281 What do we really see when we look at magnetic resonance images? Ann Neurol 2007 0.75
282 [Cannabinoids in multiple sclerosis. Opportunity or hazard?]. Nervenarzt 2004 0.75
283 Mitoxantrone (Novantrone) in multiple sclerosis: new insights. Expert Rev Neurother 2004 0.75
284 An interesting case of nuchal rigidity. Can J Neurol Sci 2011 0.75
285 Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep 2004 0.75
286 A 69-year-old man with left hemispheric necrotizing mass lesion. Brain Pathol 2009 0.75
287 The metalloproteinase-disintegrin ADAM10 is exclusively expressed by type I muscle fibers. Muscle Nerve 2008 0.75
288 Vinpocetine inhibits oligodendroglial precursor cell differentiation. Cell Physiol Biochem 2012 0.75
289 Neuronal ADAM10 Promotes Outgrowth of Small-Caliber Myelinated Axons in the Peripheral Nervous System. J Neuropathol Exp Neurol 2015 0.75
290 Bilateral medullary pyramid infarction. Neurology 2005 0.75
291 Humoral immune responses after rabies infection. Arch Neurol 2007 0.75
292 Anti-JC-virus antibody prevalence in a German MS cohort. Mult Scler 2012 0.75
293 Steering through complexity: management approaches in multiple sclerosis. Curr Opin Neurol 2016 0.75